While Shakespeare’s Hamlet pondered the existential question “To be or not to be?” the quality control director’s most pressing concern is undoubtedly “To trust or not to trust?” That’s really the question!
When most of us encounter bacteria, we reach for a sanitizer. Researchers at the Cork Cancer Research Centre in Cork, Ireland, have a much different reaction. They view these single-cell microorganisms as literal torchbearers in advancing new therapies for infectious diseases especially as it relates to cancer.
Hybrid approaches to lab management are now becoming the norm, globally, with the lure and benefit of promising a more efficient, optimal operation within labs – including reducing undue burden on lab managers.
Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe.
A group of scientists at the Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) have developed a new microscopy technique for blood cells that saves time, money, and, most importantly, is already helping to uncover new immunotherapy treatments for cancer.
The nanotech world just witnessed a revolution. For the first time in history, scientists at the University of South Carolina’s Center for Environmental NanoScience and Risk (CENR) and PerkinElmer have precisely quantified the uptake of metal nanoparticles by individual cells.
Researchers have developed an optimized and validated routine method for collecting stool samples to extract DNA for the first time. The method uses PerkinElmer's chemagic MSM I extraction instrument and is expected to accelerate microbiome research.
Research at Institut Pasteur de Lille using PerkinElmer’s Opera® High-Content Screening System and Acapella® Image Analysis Software contributes substantial new information to our understanding of M. tuberculosis.
Scientists at UCLA's David Geffen School of Medicine are working with bioluminescent, fluorescent, and positron emission tomography (PET) technologies to reduce infections in post-surgical orthopedic patients as well as fight against metabolic cancer.
Since its introduction in the early 1990s to today, 3-dimensional (3D) imaging still remains a “buzz” word that sounds a bit mysterious.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In an ovarian cancer case study, Dr. Feldman uses this instrumentation to modernize pathology.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses the instrumentation to gain insight into tumor pathogenesis.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lung cancer case study, Dr. Rimm uses this instrumentation to evaluate tumor infiltrating lymphocytes.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a colorectal case study, Dr. Galon uses this instrumentation to uncover more details about cancer and the immune system.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this instrumentation in her immune-oncology research.
Two years after forming a strategic collaboration AMRI and PerkinElmer are helping to eliminate research and clinical data silos and advance precision medicine.
Cancer researchers now can visualize more of a tumor than ever before using PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions. In a melanoma case study, Dr. Tumeh uses this instrumentation to develop biomarkers in his cancer immunology research.
Using the Attivo and SciBite TERMite platforms, researchers can now unlock the value of unstructured data found in electronic medical records, to reveal medical discoveries that would otherwise be lost in too much data.
PerkinElmer’s NexION 2000 Single Cell ICP-MS has the ability to detect metal in a single ovarian cancer cell, which will lead to new cancer strategies and therapies.
A new generation of high-content imaging systems such as the PerkinElmer Operetta CLS High Content Imaging System and Harmony High Content Imaging and Analysis Software are helping scientists to blaze new trails in cancer drug therapy.